CN105130998A - 库潘尼西的制备方法 - Google Patents

库潘尼西的制备方法 Download PDF

Info

Publication number
CN105130998A
CN105130998A CN201510618067.6A CN201510618067A CN105130998A CN 105130998 A CN105130998 A CN 105130998A CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 A CN105130998 A CN 105130998A
Authority
CN
China
Prior art keywords
reaction
kupannixi
methoxy
morpholin
yl
Prior art date
Application number
CN201510618067.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105130998B (zh
Inventor
许学农
王喆
包志坚
张文件
苏健
顾新禹
薛佳
袁玉环
Original Assignee
苏州立新制药有限公司
许学农
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州立新制药有限公司, 许学农 filed Critical 苏州立新制药有限公司
Priority to CN201510618067.6A priority Critical patent/CN105130998B/zh
Publication of CN105130998A publication Critical patent/CN105130998A/zh
Application granted granted Critical
Publication of CN105130998B publication Critical patent/CN105130998B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
CN201510618067.6A 2015-09-25 2015-09-25 库潘尼西的制备方法 CN105130998B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法
KR1020187011225A KR20180096572A (ko) 2015-09-25 2016-07-01 코판리십의 제조방법
PCT/CN2016/088091 WO2017049983A1 (zh) 2015-09-25 2016-07-01 库潘尼西的制备方法

Publications (2)

Publication Number Publication Date
CN105130998A true CN105130998A (zh) 2015-12-09
CN105130998B CN105130998B (zh) 2017-07-28

Family

ID=54716625

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510618067.6A CN105130998B (zh) 2015-09-25 2015-09-25 库潘尼西的制备方法

Country Status (3)

Country Link
KR (1) KR20180096572A (und)
CN (1) CN105130998B (und)
WO (1) WO2017049983A1 (und)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0326307A2 (en) * 1988-01-23 1989-08-02 Kyowa Hakko Kogyo Co., Ltd. Novel pyridazinone derivatives and pharmaceutical preparations containing them
JP2003252875A (ja) * 2002-03-04 2003-09-10 Lotte Co Ltd 新規プリン誘導体
CN1688582A (zh) * 2002-09-30 2005-10-26 拜尔药品公司 稠合吡咯-嘧啶衍生物
CN101631464A (zh) * 2006-12-05 2010-01-20 拜耳先灵医药股份有限公司 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017049983A1 (zh) * 2015-09-25 2017-03-30 苏州立新制药有限公司 库潘尼西的制备方法

Also Published As

Publication number Publication date
KR20180096572A (ko) 2018-08-29
CN105130998B (zh) 2017-07-28
WO2017049983A1 (zh) 2017-03-30

Similar Documents

Publication Publication Date Title
US7399758B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
AU781826B2 (en) Tricycle inhibitors of poly(ADP-ribose) polymerases
CA2563699C (en) Kinase modulators and method of use
KR20120047924A (ko) Pi3k 저해물질로서의 피리미디논
AU2004298448B2 (en) Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
Alagarsamy et al. Synthesis and antihypertensive activity of novel 3-benzyl-2-substituted-3H-[1, 2, 4] triazolo [5, 1-b] quinazolin-9-ones
AU2006289281B2 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
EP2694484A1 (en) Pyrimidine derivatives for the treatment of viral infections
Chern et al. Studies on quinazolines. 5. 2, 3-Dihydroimidazo [1, 2-c] quinazoline derivatives: a novel class of potent and selective. alpha. 1-adrenoceptor antagonists and antihypertensive agents
PT99415A (pt) Processo para a preparacao de derivados de quinazolina uteis para melhorar a activadede antitumoral
WO2005061466A1 (ja) 新規フェニルアラニン誘導体
Gao et al. Chemical fixation of CO2: efficient synthesis of quinazoline-2, 4 (1H, 3H)-diones catalyzed by guanidines under solvent-free conditions
Abdel-hafez Benzimidazole condensed ring systems: New synthesis and antineoplastic activity of substituted 3, 4-dihydro-and 1, 2, 3, 4-tetrahydro-benzo [4, 5] imidazo [1, 2-a] pyrinnidine derivatives
AU2008300827A1 (en) Novel tetrahydrofusedpyridines as histone deacetylase inhibitors
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
LaBarbera et al. Synthesis of imidazo [1, 5, 4-de] quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products
Ryabukhin et al. N-Substituted ureas and thioureas in biginelli reaction promoted by chlorotrimethylsilane: convenient synthesis of N1-Alkyl-, N1-Aryl-, and N1, N3-Dialkyl-3, 4-Dihydropyrimidin-2 (1H)-(thi) ones
KR20100081294A (ko) 간염과 같은 바이러스성 감염 치료용 이미다조[1,2-a] 피라진 화합물
WO2016161282A1 (en) Heterocyclic compounds as lsd1 inhibitors
AU2008318137B2 (en) Purification method of pemetrexed salts,sodium salts and disodium salts
KR101934096B1 (ko) 이델라리십의 제조방법
CN101983191B (zh) 作为hsp90抑制剂的肟衍生物
CN104496983B (zh) 一种帕博西尼的制备方法
CN102659815B (zh) 一种制备选择性抗凝血药替卡格雷及其中间体的方法
CN102083314A (zh) Parp抑制剂化合物、组合物以及使用方法

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
GR01 Patent grant